Retrospective survey on efficacy of cefixime-ofloxacin 400 milligram sustained release fixed-dose combination tablet for enteric fever in community settings of India

Saiprasad Patil, Krishnaprasad Korukonda, Amit Bhargava


Background: The World Health Organization (WHO) estimate for annual global incidence of typhoid fever, about 21 million cases, is probably an underestimate because of poor diagnostics. Multi-drug resistant (MDR) isolates and nalidixic resistant isolates have limited the choice of oral drugs available for the treatment of typhoid fever. Recently the Indian regulatory authority approved an oral fixed dose combination (FDC) of cefixime and ofloxacin for the treatment of typhoid fever.

Methods: Retrospective survey was planned to observe the efficacy of cefixime-ofloxacin 400 mg sustained release (SR) FDC tablet for enteric fever in community settings of India. Family physicians involved in the management of enteric fever cases were selected across 4 zones (East, South, West, and North) each by convenient sampling to have uniform representation of population across the country. Each physician was given survey questionnaire booklet containing survey forms.

Results: Total 78 family physicians participated in the survey with 881 completed questionnaire forms. Hypertension, diabetes were present in 83% (N=244) patients with comorbid conditions. One hundred and fifty four (17.4%) cases revealed history of relapse or recurrence. Fever clearance rate of 97% was observed in overall evaluable population. Sub analysis in high risk cases (relapse/recurrence) showed equally good response to the combination as cases without defervescence on day 3 and day 7 were only 21.4% and 1.3% respectively.

Conclusions: Based on the present study we believe that cefixime-ofloxacin 400mg SR FDC to be an appropriate choice in the management of resistant enteric fever cases, especially in presence of comorbid conditions like hypertension or diabetes which adds to excess pill burden.


Sustained release (SR), MDR isolates, Fixed-dose combination (FDC), retrospective survey

Full Text:



Buckle GC, Walker CLF, Black RE. Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010. J Glob Health. 2012;2(1):010401.

Wain J, Hendriksen RS, Mikoleit ML, Keddy KH, Ochiai RL. Typhoid fever. Lancet. 2014;385(9973):1136-45.

Wain J, Hosoglu S. The laboratory diagnosis of enteric fever. J Infect Dev Ctries. 2008;2(06):421-5.

D S. The diagnosis, treatment and prevention of typhoid fever, 2013. (WHO/V&B/03.07)

Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ. 2008;86(4):260-8.

Harish BN, Menezes GA. Antimicrobial resistance in typhoidal salmonellae. Indian J Med Microbiol. 2011;29(3):223-9.

Pandit A, Arjyal A, Day JN, Paudyal B, Dangol S, Zimmerman MD, et al. An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. PLoS One. 2007;2(6):e542.

Fixed dose combinations approved by DCG (I) since 1961 till December, 2013.

Jaimini M. Sustained release matrix type drug delivery system: A review. Journal of Drug Delivery & Therapeutics, 2012.

Naik M, Braganza L, Nair S. Open non-comparative evaluation of fixed dose combination of cefixime and ofloxacin in the treatment of uncomplicated typhoid fever. Ind Med Gaz. 2010;415-20.

Faruqui AA. Evaluation of efficacy and safety of fixed dose combination of cefixime and ofloxacin (CO2 Tablet) in the management of typhoid fever. Indian J Basic Appl Med Res. 2012;1(4):296-303.

Kumar A, Kumar J, Iyer SB, Kumar PK. Impact of pill burden and socio-economic status of patients on adherence to pharmacologic therapy in elderly. West Lond Med J. 2014;6(1):23-8.

Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-9.